Nova Eye Medical (EYE) Discussion, page-2695

@elpassive

I think it is quite likely we could see this. Not only would the price have to double with revenue to maintain the same valuation multiple, but we would likely see a jump from the very small valuation currently being applied (EV around 2x revenue), to a much higher multiple more suitable for a growth stock (8-10x). So that would be 2x for the sales growth alone, and then another 4-5x increase on top of that to get this to a more appropriate valuation multiple. If they announce profitability at the same time, which is quite likely given that they are predicting cash flow positive by FY25, that would likely give the share price an extra bump in addition to all of that as well. That's what happens when you have a stock valued at only $50m, the rerates can happen very quick and can be very large. As it increases in size the rerate only speeds up, as larger investors gain access to it and quickly join other investors in taking positions.